Abstract
We have developed a specific reverse ELISA to investigate the potential of the domain III of the West Nile virus envelope protein to detect virus-specific antibodies. For this purpose, the domain III antigen was expressed in Escherichia coli, refolded and directly labelled with peroxidase. By mixing serum samples with the enzyme-labelled antigen, immune complexes will form that are simultaneously recognized by rheumatoid factor coated microtiter plates. Specific antibodies to the domain III were found in 160 out of 206 sera of patients with neutralising antibodies to West Nile virus (77.6% sensitivity). The antigen differentiated reliably between sera of West Nile virus- and dengue virus-infected patients. In combination with indirect immunofluorescence, to exclude four false-positive samples, the specificity was 100% (280 samples). Assuming a prevalence rate of anti-West-Nile virus antibodies of 5%, the positive and negative predictive values were 93.3% and 98.8% respectively. These results indicate that the reverse ELISA using a specific portion of the envelope antigen of West Nile virus is especially suitable for studies on the prevalence of West Nile infections in affected countries.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: European Journal of Clinical Microbiology & Infectious Diseases
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
